Know Long COVID.

What it is

Long COVID is the umbrella term for symptoms that persist or develop after acute SARS-CoV-2 infection. The WHO defines post-COVID-19 condition as symptoms lasting at least two months and not explained by an alternative diagnosis, typically starting within three months of acute infection. The CDC uses a similar 4-week threshold. The patient community has used "Long COVID" since 2020, after Elisa Perego coined it on Twitter in May 2020 to name what she and others were experiencing.

Long COVID is not one disease. It is a syndrome with multiple overlapping phenotypes: post-ICU sequelae, cardiopulmonary damage, dysautonomia (often POTS), post-viral fatigue (often meeting ME/CFS criteria), and organ-specific damage. Most patients have features of more than one phenotype. The mechanisms include persistent viral antigen, microvascular damage and microclots, autoimmunity, mitochondrial impairment, reactivated herpesviruses (EBV, HHV-6), and central nervous system inflammation.

Long COVID is not deconditioning, anxiety, or laziness. The "try harder" framing of the early pandemic has been thoroughly contradicted by the published research. Patient communities have done as much to shape the science as the funded research, particularly on PEM, dysautonomia, and microclots.

Scale and demographics

Long COVID is the largest mass-disabling event in modern times. Estimates vary by definition and methodology but converge around:

• ~65 million people globally meet some definition of Long COVID (mid-2020s estimates).
• 5-15% of acute COVID infections produce symptoms lasting more than 12 weeks; the rate is lower for vaccinated and reinfections but never zero.
• Roughly two-thirds of patients are women, and onset peaks in working-age adults (30s-50s).
• Most patients were healthy and high-functioning before infection. That contrast is part of why the loss is sharp.
• Reinfections increase Long COVID risk; "mild" acute infections still produce Long COVID at meaningful rates.

Phenotypes

Long COVID is not one disease. At least four overlapping phenotypes are recognised:

• Post-acute hospitalisation / ICU. Patients who were severely ill during acute COVID; their recovery picture includes lung damage, post-ICU weakness, and post-traumatic effects. Largely well-served by post-COVID rehab clinics.
• Cardiopulmonary phenotype. Chest pain, dyspnea, palpitations, exercise intolerance, sometimes with measurable cardiac or pulmonary abnormalities. Invasive CPET often shows abnormal exercise physiology even when standard tests look normal.
• Dysautonomia / POTS phenotype. Standing heart rate spikes, lightheadedness, post-meal and heat-related crashes, brain fog on standing. The most common single subtype; often missed because clinicians don't measure standing heart rate.
• Post-viral fatigue / ME/CFS phenotype. Profound fatigue, post-exertional malaise, unrefreshing sleep, cognitive impairment. A substantial portion of Long COVID patients meet IOM 2015 ME/CFS criteria; the practical management is identical.

Many patients have features of multiple phenotypes. The dysautonomia and ME/CFS phenotypes overlap so heavily that some researchers argue they're the same picture viewed from different clinical angles.

Mechanisms

The biology of Long COVID is plural and active. Major mechanistic hypotheses with evidence behind them:

• Persistent viral antigen. SARS-CoV-2 spike protein and viral RNA have been found in tissue (gut, brain, lymph nodes) of Long COVID patients months after acute infection. Whether the virus is still replicating or just persisting as antigen reservoir is debated.
• Microvascular damage and microclots. Persistent fibrinoloid microclots blocking small vessels have been identified in subsets of patients (Pretorius, Kell, and others). Endothelial dysfunction shows up on imaging and biopsy.
• Autoimmunity. Autoantibodies against adrenergic and muscarinic receptors, ACE2, and other targets are elevated in subsets. The BC007 drug (autoantibody-neutralising) is in trials.
• Mitochondrial impairment. Reduced ATP production and abnormal aerobic recovery are documented on the Workwell 2-day CPET protocol, similar to ME/CFS.
• Reactivated herpesviruses. EBV, HHV-6, and other latent viruses are commonly reactivated in Long COVID; antiviral trials are ongoing.
• Central nervous system inflammation. Iwasaki and colleagues have shown reduced regulatory T cells, pro-inflammatory microglia, and persistent NF-kB activation in Long COVID cognitive symptoms.
• Vascular dysfunction with cerebral hypoperfusion. Standing causes large drops in cerebral blood flow even when standard HR/BP look near-normal.
• Gut microbiome disruption. Distinct microbiome signatures persist; clinical translation is early.

Post-vaccine syndrome overlap

A small subset of patients describe a syndrome after COVID vaccination that closely resembles Long COVID, sometimes called "post-vaccine syndrome" or "long-vax." Symptom patterns overlap: POTS, MCAS-like reactions, dysautonomia, fatigue, brain fog, small fibre neuropathy. The mechanism is contested and patient numbers are much smaller than infection-related Long COVID, but the syndrome is real for the people experiencing it.

This is a charged topic with strong views on both sides. The honest position: acknowledging the smaller subset who experience post-vaccine symptoms does not diminish the well-established overall benefit of vaccination, and conversely, dismissing those patients pushes them out of medical care. They deserve the same diagnostic workup and pacing-and-comorbidity-treatment approach as infection-related Long COVID patients.

Related conditions and overlaps

Long COVID overlaps heavily with ME/CFS (substantial portion of patients meet criteria), POTS (most patients meet criteria on a proper stand test), MCAS (many develop a mast-cell pattern after infection), hEDS (uncovered rather than caused), reactivated herpesviruses, and autoimmune disease. Chapter six covers each in depth.

Support for family and loved ones

Long COVID has been hard on the people around patients in a specific way: the patient was usually healthy before. The contrast between who they were and who they are now is sharp and visible. Loved ones often need help understanding that recovery is not on the patient's timeline, that pushing through makes things worse rather than better, and that the dismissive framing they may have heard from clinicians in 2021-2022 has been thoroughly contradicted by the research.

What helps: taking cancellations gracefully, doing the cognitive labour (medications, appointments, insurance), being the calm voice when the patient is being told to try harder, and learning to recognise PEM warning signs. What hurts: suggesting exercise, suggesting it's anxiety, comparing them to other people who "got over COVID quickly," and treating good days as proof of recovery.

Before and after

The defining personal experience of Long COVID is the contrast. Most patients were healthy and high-functioning weeks before they got sick. Many were athletes, parents managing young children, executives, healthcare workers, students. The version of themselves before the infection is unusually recent, unusually clear, and unusually different from the version that exists now.

That recency makes the grief sharper than in chronic illnesses that come on gradually. There is a specific date, an inciting event, a known cause. Patients can name the week things changed. The bargaining ("if I just rest harder, eat cleaner, push through, I'll get back to who I was") is intense, and the realisation that the pre-illness self may not return is some of the harder integration work in modern chronic illness.

Medical gaslighting

The same dismissal cycle that hit ME/CFS and POTS patients in the prior decades arrived for Long COVID patients within months of the pandemic. The early framing in many clinics was: deconditioning, anxiety, "try exercise," "have you tried therapy?" Patients were told their symptoms were psychogenic in the same week that researchers were publishing endothelial-dysfunction and microclot data.

By 2023-2024 the medical literature had moved decisively. The gaslighting reduced but did not disappear, particularly outside specialist clinics. Patients who get told their symptoms are anxiety despite a workup that hasn't included a stand test, a sleep study, ferritin, EBV serology, and at minimum a screen for PEM are still common. The fix is largely clinician-by-clinician.

One sentence the community keeps repeating: "Anxiety doesn't produce a 40-bpm rise on standing, a 30% drop in cerebral perfusion, or microclots on imaging. Stop telling us that and start measuring."

Lost careers and income

Long COVID is a mass economic event. The line items that the medical world rarely engages with:

• Lost jobs. Many Long COVID patients lose their careers within 6-18 months of infection, particularly those in physically or cognitively demanding work.
• Lost income from reduced hours, transition to disability, or being unable to return after FMLA / equivalent.
• Insurance churn. Lost-job-lost-insurance is a US-specific harm pattern that compounds the disease burden.
• Medical costs. Specialist visits, autonomic testing, off-label medications, wearables, supplements. Real money over years.
• Family income shifts. Spouses often pick up caregiver and household-management load.
• Career re-entry difficulty. The gap on a CV is hard to explain; energy limits constrain the kinds of jobs available.

Patients who manage this well usually do three things early: start disability paperwork during the worst months (documentation is easier than later); contact a disability lawyer if income is at stake; learn the patient-assistance programmes for any biologic or expensive medication.

Identity loss

Long COVID strikes during peak career and family years for most patients. Loss of athletic identity, loss of professional identity, loss of parental capacity, loss of the social roles built over a lifetime. The integration work is the same as the other diseases in this reference: fighting hard for who you were, hitting a wall, accepting the disease as a constraint, then building a smaller life with intention inside the constraint. Most patients describe the same arc; few get to skip the bargaining stage.

Isolation

Long COVID is socially isolating in specific ways. Many patients cannot tolerate ordinary social environments (restaurants too noisy, parties too late, alcohol problematic, in-person meetings expensive). The communities they used to belong to (sports teams, gyms, networking events, conferences) often fade because the patient cannot keep up the cadence. Most sustaining community for many Long COVID patients is asynchronous and online: r/covidlonghaulers, Body Politic, patient-led WhatsApp groups, severe-illness Twitter/Bluesky communities.

Mental health

Depression and anxiety are common in Long COVID, and the relationship is widely misunderstood. The medical literature initially framed Long COVID as a mental-health condition; the patient experience and the published data have established it as a biological condition that produces mental-health consequences. Living with a serious dismissed energy-limiting illness produces depression and anxiety. Treating only the mental-health symptoms rarely resolves the underlying disease.

Treatment is worthwhile. Antidepressant choice matters: SSRIs are often poorly tolerated in Long COVID; SNRIs, low-dose tricyclics, and low-dose abilify are often better-tolerated. Trauma-focused therapy can help patients who have been through severe acute illness, ICU, or aggressive gaslighting.

Long COVID touches every body system. The list below is comprehensive, not a checklist. Different phenotypes affect different patients; the same patient's pattern can shift over months. PEM is the single most important symptom to screen for because it changes every exercise recommendation.

Post-exertional malaise (PEM)

PEM affects roughly half of Long COVID patients. It is the same phenomenon described in ME/CFS: a delayed, disproportionate worsening of all symptoms 24-72 hours after exertion. Triggers can be physical (a walk, household chores), cognitive (a long meeting, sustained reading), or emotional (a stressful conversation, joyful intensity). Repeated PEM episodes can cumulatively lower the patient's baseline.

If you have PEM, the standard exercise advice for post-viral recovery is wrong. Graded exercise therapy has caused documented permanent harm in Long COVID patients with PEM, the same evidence base that led NICE to remove GET from its ME/CFS guideline in 2021. Pacing comes first.

Cognitive and neurological

Brain fog

Slowed thinking, word-finding loss, short-term memory disruption, difficulty following conversation. Neuropsychological testing in Long COVID shows real processing-speed deficits, often in the range of "20 years older than expected." Often the most disabling symptom for work and study. Frequently worse when upright (reduced cerebral perfusion contributes).

Headaches

Tension-type, migraine-pattern, and orthostatic head pressure are all common. New persistent headache after COVID is a recognised phenotype.

Sleep disturbance

Unrefreshing sleep, insomnia, fragmented sleep, sometimes a reversed circadian rhythm (foggy in the morning, clearer in the evening). A sleep study is worth requesting; sleep apnea is the most-missed treatable contributor.

Dizziness and lightheadedness

Usually from dysautonomia / POTS. Often misread as anxiety. Improves with the same fluids / salt / compression / medication approach as standalone POTS.

Small fibre neuropathy

Burning, tingling, electric pain, and autonomic neuropathic features. Confirmed on skin biopsy in a meaningful subset.

Smell and taste

Persistent anosmia, parosmia (distorted smell, often unpleasant), or ageusia. The most "COVID-specific" symptom; some patients recover, some don't. Olfactory training has weak but real evidence.

Cardiopulmonary

Dyspnea

Breathlessness disproportionate to exertion. Standard pulmonary function tests are often normal; invasive CPET shows abnormal exercise physiology in many patients. The cardiopulmonary phenotype of Long COVID is real and measurable; standard tests can miss it.

Chest pain

Common, usually non-cardiac in mechanism (often costochondritis, microvascular, or autonomic), but new chest pain warrants cardiac workup at least once.

Palpitations and tachycardia

Standing tachycardia is most often POTS-related. Resting tachycardia and palpitations can persist for months after COVID. Holter monitor is reasonable to rule out arrhythmias; in most cases it's autonomic.

Exercise intolerance

Activity that was once easy becomes exhausting. In the PEM-positive subset, exercise also triggers cumulative crashes. In the dysautonomia-dominant subset, upright cardio is particularly hard.

Autonomic and POTS

Most Long COVID patients meet POTS criteria on a properly-done active stand test (≥30 bpm rise within 10 minutes of standing, sustained, without orthostatic hypotension). The picture is the same as standalone POTS:

• Standing heart rate spikes
• Lightheadedness, presyncope, occasional fainting
• Brain fog on standing
• Heat intolerance, post-meal crashes
• Coat-hanger neck/shoulder pain
• Tremor and adrenaline surges (hyperadrenergic subset)

Treating the POTS, with fluids, sodium, compression, beta-blockers or ivabradine, fludrocortisone, midodrine, often lifts a whole functional level even when the rest of the Long COVID picture doesn't improve directly.

MCAS-like and immune

Flushing, hives, food sensitivities

Many Long COVID patients with no prior allergy history develop a mast-cell-activation pattern after COVID: flushing, hives, food reactions, drug reactions, dermatographism (skin welts when scratched). Often responds to H1/H2 antihistamines and mast-cell stabilisers.

Reactivated viruses

EBV, HHV-6, and CMV reactivation is common in Long COVID. Patients describe "feeling fluey all the time," with sore throat, swollen glands, and the kind of malaise that suggests the immune system is fighting something it can't quite finish.

Allergies appearing or worsening

New allergies, worsened atopic conditions, and new sensitivities to medications and foods are commonly reported.

GI symptoms

The gut is involved in Long COVID more often than the early literature suggested. Common patterns:

• Diarrhoea, IBS-like symptoms
• Gastroparesis (delayed gastric emptying)
• Nausea, post-meal pain or crash
• New food sensitivities (overlap with MCAS)
• Microbiome disruption with distinct post-COVID signatures
• Persistent viral antigen in gut tissue (research finding)

Other symptoms

• Muscle and joint pain. Often diffuse, sometimes meeting fibromyalgia criteria after onset.
• Skin. Hair loss (telogen effluvium, often months after acute infection), rashes, eczema flares, livedo, COVID toes.
• Endocrine. Thyroiditis (worth checking TSH and free T4), menstrual irregularities, post-COVID diabetes (rare but documented).
• Eye. Dry eyes, visual disturbances, occasionally uveitis.
• Audio-vestibular. Tinnitus, sound sensitivity, dizziness, balance issues.
• Sexual and reproductive. Reduced libido, erectile dysfunction, menstrual cycle changes; often improve with overall illness improvement.

Diagnostic workup

There is no single test for Long COVID. Diagnosis is clinical (symptoms persisting or developing after COVID, lasting at least 4-12 weeks, not explained by another condition). The purpose of the workup is to identify treatable comorbidities and rule out major mimics. A reasonable initial workup:

• FBC, CRP, ESR, ferritin, B12, folate, vitamin D, magnesium, TSH and free T4, HbA1c, U&E, LFTs. Cheap, useful, frequently surfacing treatable deficiencies. Note: ferritin under 75 is functionally deficient even within the "normal" range.
• EBV, CMV, HHV-6 serology and quantitative PCR where reactivation is suspected. Reactivation is common and sometimes treatable.
• Active stand test (NASA Lean) or tilt-table test. The single most-missed treatable diagnosis in Long COVID is comorbid POTS. Ten minutes of bedside testing.
• Sleep study. Sleep apnea is the single most-missed treatable mimic of post-viral fatigue. Worth requesting even if you don't think you have apnea.
• Echocardiogram, ECG, Holter monitor where cardiopulmonary symptoms are prominent. Rule out arrhythmia, structural heart disease.
• Pulmonary function tests, sometimes invasive CPET where dyspnea is prominent. Standard PFTs can miss the Long COVID exercise-physiology abnormalities.
• Skin biopsy for small fibre neuropathy when neuropathic pain or autonomic neuropathic features are prominent.
• Tryptase, urinary methylhistamine, and MCAS workup when flushing, hives, food reactions are prominent.
• Vitamin D, iron studies, magnesium if not already covered above; deficiencies are routine.
• Autoimmune panel (ANA, RF, anti-CCP, anti-TPO) where the picture suggests autoimmunity.

Differential and rule-outs

Conditions that can look like Long COVID, overlap with it, or be the better diagnosis:

• ME/CFS. Overlap rather than differential; a substantial portion of Long COVID patients meet ME/CFS criteria. The practical management is identical.
• POTS. Overlap rather than differential; most patients meet POTS criteria on testing.
• MCAS. Frequently appears or worsens after COVID. Worth screening when the picture suggests it.
• Sleep apnea. Most-missed treatable mimic. Worth a sleep study.
• Thyroid disease. Post-viral thyroiditis is documented; check TSH, free T4, anti-TPO.
• Iron deficiency. Ferritin under 75 is functionally deficient for many patients.
• Reactivated EBV/HHV-6. Worth treating when active.
• Depression / anxiety. Often consequences of the illness, sometimes contributors; treat where present but don't accept as the whole picture.
• Acute COVID complications (pulmonary fibrosis, blood clots, organ damage) need their own workup.

Pacing first

If you have PEM, pacing is the foundation of every other intervention. The work is finding your energy envelope and staying inside it. The same methods used in ME/CFS apply directly:

• Heart-rate ceiling pacing. Stay below your anaerobic threshold (often 60-80% of (220 minus age), more precisely measured by CPET). Use a wearable with alarms.
• Time-budget blocks. Divide the day into 30-60-minute blocks; assign activity levels; reserve recovery blocks proactively.
• Energy envelope tracking. Log activity vs. how you feel 24-72 hours later until your individual envelope becomes visible.
• Include cognitive and emotional load. A long meeting, a difficult conversation, sustained reading all count.
• Bank rest, plan crashes. Some events are worth a crash; bank rest before and after.

Pacing isn't permanent. As the disease quiets (or as treatable comorbidities get treated), the envelope expands. The work is staying inside it now so you can rebuild capacity later, rather than wrecking your baseline through cumulative PEM.

Treat the comorbidities

Most of the functional improvement in Long COVID comes not from treating "Long COVID" but from treating the conditions it has unmasked or triggered. The single most useful sentence in this chapter:

Treat the POTS. Treat the MCAS. Treat the sleep apnea. Treat the iron deficiency. Treat the reactivated EBV. Each of these can move a whole functional level.

• POTS. 2-3L fluid, 8-10g sodium (cleared with your doctor), waist-high compression. Beta blockers / ivabradine for tachycardia, midodrine for pooling, fludrocortisone for blood volume.
• MCAS. H1 antihistamines (cetirizine, fexofenadine), H2 antihistamines (famotidine), mast-cell stabilisers (ketotifen, cromolyn). Low-histamine diet for the responsive subset.
• Sleep apnea. CPAP can be transformative in the apnea subset.
• Iron deficiency. IV iron is often more effective than oral. Target ferritin 75-100.
• Reactivated herpesviruses. Valacyclovir, valganciclovir for the subset with documented reactivation and a clinician willing to trial.
• Vitamin D, B12, magnesium. Repletion to mid-normal range.

Medications

No drug is approved specifically for Long COVID. Off-label options widely tried in patient communities:

• Low-dose naltrexone (LDN, 1.5-4.5 mg). The most-discussed off-label option. Modulates microglial inflammation. Patients report meaningful function gains; well-tolerated; cheap. Worth a trial.
• Mestinon (pyridostigmine). Particularly useful in the POTS-dominant subset. Improves nerve signalling.
• Low-dose abilify (LDA, 0.25-2 mg). Off-label for cognitive symptoms and the reversed circadian pattern. Stanford ME/CFS clinic has published case series.
• Low-dose amitriptyline or nortriptyline. Sleep and pain; often tolerated at very low doses.
• POTS medications. Propranolol, ivabradine, midodrine, fludrocortisone where POTS is comorbid (most patients).
• Antihistamines. H1 and H2 widely useful for the MCAS-overlap subset.
• Antivirals. Valacyclovir, valganciclovir for documented herpesvirus reactivation in selected patients.
• SSRIs / SNRIs / LDA for depression-and-anxiety overlap. SSRIs often poorly tolerated; SNRIs and LDA usually better.

Long COVID patients are often exquisitely sensitive to medication, similar to ME/CFS. Start low, titrate slow, allow 6-8 weeks per trial.

What helps versus what harms

Experimental and emerging

Long COVID has driven the largest burst of post-viral-illness research in history. Honest map of the experimental landscape, with caveats explicit:

• BC007. A drug that neutralises autoantibodies against adrenergic and muscarinic receptors. Phase 2 trials in Long COVID. One of the most-watched candidates.
• Triple anticoagulation. Heparin + clopidogrel + apixaban regimens for the microclot subset. Private clinics report benefit; serious bleeding risk; not yet enough controlled data. Not for self-treatment.
• Paxlovid for established Long COVID. The Stanford PaxLC trial showed limited benefit. Mechanistic interest in persistent viral antigen remains; the drug as a Long COVID treatment is not settled.
• Anti-IL-6 (tocilizumab) and other immunomodulators. Used in selected refractory autoimmune-pattern patients. Off-label, expensive, risks.
• IVIG. Considered in selected patients with strong autoimmune evidence; expensive; mixed evidence.
• GLP-1 agonists (tirzepatide, semaglutide). Anecdotal reports of significant improvement in some patients; mechanism debated (possibly anti-inflammatory or via gut-microbiome routes).
• FMT and microbiome therapies. Research interest is real; clinical translation is early.
• Stellate ganglion block. Calms sympathetic outflow; explored for the hyperadrenergic / dysautonomic subset; mixed evidence.
• Brain-retraining programmes (DNRS, Gupta, Pain Free You). Contested. Some patients report benefit (plausibly via stress reduction); patient communities flag the harm pattern of abandoning pacing to try a "cure." Approach with eyes open, never as a substitute for foundational care.
• HBOT (hyperbaric oxygen therapy). Some published RCTs (Israel) showed cognitive improvement; replication and access are limited.

Tools, apps, and the kit patients actually use

Pacing and wearables

• Rox. The companion app this reference is built alongside. Connects your wearable to your symptom log, PEM events, and patterns across the Long COVID / POTS / MCAS / fatigue cluster. Built-in pacing layer: heart-rate ceiling and energy-envelope tracking. Turns months of data into the patterns a clinician will actually act on. App Store.
• Heart-rate ceiling pacing on any wearable (Apple Watch, Garmin, Fitbit, Polar, Whoop, Oura). Set an alarm at your anaerobic threshold. Chest straps are more accurate than wrist-based at sustained low intensities.
• Visible (armband + app). Continuous HRV-based exertion tracking with "pace points" per task. Designed for the Long COVID / ME-CFS / POTS cluster. Community is split on whether the subscription cost is justified.
• Polar H10 chest strap. The community's reference standard for accurate low-intensity HR tracking.

Sensory and environmental kit

• Bedside-everything setup. Water, electrolytes, salty snacks, medications, phone charger, eye mask, ear protection within reach. Standing to retrieve things you forgot is the most-paid-for unnecessary exertion.
• Shower stool. Showering is one of the most expensive activities for many Long COVID patients.
• Compression garments (waist-high or abdominal, 20-30 or 30-40 mmHg) for the POTS subset.
• Cooling vest / fan for heat-intolerant patients.
• Mobility aids for high-cost days. A folding cane-seat, a rollator with a seat, a wheelchair for travel and crowds. Situational use doesn't accelerate the illness; it makes a wider life possible.

Finding the right clinician

• Bateman Horne Center physician resources; one of the few centres with Long COVID + ME/CFS expertise.
• Open Medicine Foundation for research links and clinical centres.
• Specialised Long COVID clinics at major academic medical centres (Mount Sinai, Stanford, Yale, Johns Hopkins, UCSF, others). Quality varies; ask whether they pace, screen for POTS / MCAS, and follow post-2022 guidance.
• MEAction for the ME/CFS-aware clinician pathway.
• Patient-Led Research Collaborative resources.

Prognosis

Honest prognosis for Long COVID is harder to give than for most chronic illnesses, partly because the disease is recent (less than five years of post-2020 data) and partly because the phenotypes have such different trajectories. What is reasonably established:

• Most patients improve over the first 12-18 months, often substantially. The rate of improvement slows after that.
• A meaningful minority remain disabled at the 2+ year mark, particularly those with the PEM-positive / ME/CFS-overlap phenotype.
• Patients who pushed through during the early months (returned to full work, attempted aggressive exercise, ignored PEM) frequently have worse long-term outcomes than those who paced from the start.
• Reinfections meaningfully worsen many patients; protecting against reinfection where possible is reasonable.
• Treating comorbid POTS, MCAS, sleep apnea, and reactivated viruses often moves a whole functional level even when the underlying Long COVID doesn't change directly.

The pattern most patients should plan for: not a return to who you were on day one, but a workable life that you build inside the constraint over years, often with intermittent good periods and rare strong periods, with the best long-term outcomes for the patients who paced strictly early.

Recovery, with caveats

The Long COVID recovery-story ecosystem is large, recent, and contested in the same way the ME/CFS one is. A few things worth knowing:

• Many "recovery" stories come from patients who were mild to begin with, optimised lifestyle, regained 20-30% of function, and redefined "recovered." That's adaptation, and it's real, but it's not the same as reversing the disease in a severe patient.
• Many recovery stories come from people who never had PEM in the first place; their disease has a different prognosis.
• Brain-retraining cure content (DNRS, Gupta, Pain Free You, ANS Rewire) is popular and is associated with both reported benefit (plausibly stress reduction) and reported harm (patients abandoning pacing and crashing).
• The recovery-creator industry selects for the recovered; patients who tried the same protocols and got worse rarely make videos.

Substantial improvement is possible. The patients who improve almost universally describe the same arc: aggressive rest at onset, strict pacing, treating comorbidities, finding one good clinician, and accepting the disease as a long arc rather than a problem to solve in six months. Be skeptical of cure narratives; be open to patient stories of slow, hard-won improvement.

Daily functioning

• Mornings can be a difficult window, particularly with reversed circadian rhythm (foggy on waking, clearer in the evening). Many patients function best in the late afternoon.
• Standing tasks are deceptively expensive. Showering, cooking, queueing, getting ready cost more than they look like they should. A stool in the kitchen, shower stool, bedside-everything setup help significantly.
• Cognitive load counts. A demanding email, a difficult conversation, a long meeting all draw on the same energy budget as physical activity.
• Heat is a major variable for the dysautonomia subset. Hot showers, summer, fevers can turn a manageable week into a difficult one.
• Travel costs disproportionately. A flight or a long drive can cost the rest of the week.

Work and disability

The Long COVID disability picture is significant. Estimates suggest millions of working-age adults are out of the workforce or working reduced hours because of Long COVID. The practical realities:

• Mild Long COVID: often compatible with part-time, remote, or accommodated work. Pacing remains essential.
• Moderate Long COVID: full-time work is usually unsustainable; many patients reduce hours, move to remote, or transition to disability over months.
• Severe Long COVID: work is not possible; the priority becomes disability paperwork and accommodation for daily life.

Start disability paperwork early. Documentation is easier in the worst months than after partial adaptation. Long COVID disability claims are routinely denied initially in many jurisdictions; appeals are part of the standard pathway. Document everything: symptom diaries, PEM episodes, missed work, hospitalisations, specialist letters, comorbidity diagnoses (POTS, MCAS, ME/CFS each strengthen the claim).

Relationships

Long COVID is hard on relationships, particularly because the patient was usually healthy when the relationship started. Patient-community-tested advice:

• Be honest about the illness early. Vague descriptions ("I get tired easily") invite vague expectations.
• Educate one person who will be your advocate at medical appointments. The cognitive load of advocacy alone is too high during flares.
• Dating with Long COVID is possible. Many patients in the community recommend declaring the illness in dating profiles; it reduces anxiety and filters for people who can show up.
• Parenting through Long COVID, especially with young children, is gruelling. Build in support that doesn't depend on the patient. Many partnerships have not survived this; many others have come out closer for the reorganisation.

Adapting life around the illness

The patients who live well with Long COVID almost universally describe the same arc: months of fighting hard for the old self, hitting a wall, accepting the disease as a constraint, then designing a meaningful life inside the constraint. Practical engineering that helps:

• Build the environment around the illness: bedside-everything, shower stool, mobility aids by default, cooling gear in summer, electrolyte stash for the POTS subset.
• Choose accessible activities: reading, audiobooks, short asynchronous social contact, low-stakes creative work.
• Lower the metabolic cost of basic care: pre-cooked meals, paid help where possible, the unsentimental decisions about laundry, cleaning, and errands.
• Build slack into every plan; expect the cost two days later.
• Find one or two people who will keep believing the illness even on good days.
• Protect against reinfection where possible (masking, ventilation, vaccination per current guidance).

Long COVID rarely sits alone. The same chronic-illness cluster that has been overlapping for decades (ME/CFS, POTS, MCAS, hEDS, fibromyalgia) now intersects with Long COVID in ways that are increasingly recognised. Recognising the overlaps matters because treating each one separately can move a whole functional level even when the underlying Long COVID doesn't change directly.

ME/CFS overlap

A substantial portion of Long COVID patients (estimates from a third to over half in some cohorts) meet IOM 2015 ME/CFS criteria. The defining feature is post-exertional malaise. The practical management is identical to standalone ME/CFS: pacing first, refuse GET, treat the comorbidities, prepare for a long arc. The ME/CFS reference on this site goes deeper on PEM, pacing protocols, and the experimental landscape.

The framing question that matters: whether Long COVID with PEM is "ME/CFS triggered by SARS-CoV-2" or "Long COVID phenotype that resembles ME/CFS" is partly semantic. For practical care, treat as ME/CFS.

POTS

Most Long COVID patients meet POTS criteria on a properly-done active stand test. This is the single most-missed treatable comorbidity in Long COVID. The picture is the same as standalone POTS:

• Standing heart rate jump of ≥30 bpm sustained, without orthostatic hypotension
• Lightheadedness, brain fog on standing, post-meal crashes, heat intolerance
• Three main subtypes: neuropathic, hyperadrenergic, hypovolemic

Treatment is the same as standalone POTS: fluids (2-3L), sodium (8-10g), waist-high compression, beta blockers or ivabradine for tachycardia, midodrine for pooling, fludrocortisone for blood volume. Many Long COVID patients describe POTS treatment as the single highest-leverage intervention. The POTS reference on this site covers the full picture.

MCAS

Many Long COVID patients develop a mast-cell-activation pattern after infection, even with no prior allergy history. Symptoms: flushing, hives, food sensitivities, drug reactions, dermatographism, GI symptoms, anxiety-like adrenaline surges. Often responds to H1 antihistamines (cetirizine, fexofenadine), H2 antihistamines (famotidine), mast-cell stabilisers (ketotifen, cromolyn), and a low-histamine diet for the responsive subset.

If you notice that you've become reactive to medications, foods, or environments that didn't trouble you before COVID, MCAS is worth raising with your clinician. The workup (tryptase, urinary methylhistamine) has imperfect sensitivity, so a careful clinical history matters.

Microclots and vascular dysfunction

Research from Pretorius, Kell, and others has shown persistent fibrinoloid microclots blocking small blood vessels in Long COVID patients. The hypothesised mechanism: chronic microvascular blockage causing tissue hypoperfusion, contributing to fatigue, brain fog, and cardiopulmonary symptoms.

Triple anticoagulation regimens (heparin + clopidogrel + apixaban) have been trialled in private clinics with reports of significant benefit. Risks are real (bleeding), the evidence base is still early, and most academic centres are waiting for controlled trial data before recommending. Worth knowing as a serious research direction; not yet a standard treatment. Not for self-treatment.

Reactivated herpesviruses

EBV, HHV-6, CMV, and varicella-zoster reactivation is common in Long COVID. Patients describe feeling "fluey all the time," with sore throat, swollen glands, and persistent malaise that suggests ongoing immune activity. Quantitative PCR can document active reactivation; antiviral trials (valacyclovir, valganciclovir) are used in selected patients.

Worth screening when the picture suggests it. Some patients report substantial improvement on antiviral courses, particularly for the EBV-reactivation subset; others see little benefit. Treatment course is months, not weeks.

Autoimmune overlap

Autoantibodies against adrenergic and muscarinic receptors, ACE2, and other targets are elevated in subsets of Long COVID patients. New autoimmune disease (Hashimoto's thyroiditis, lupus, RA, type 1 diabetes) has been reported as a post-COVID phenomenon. The BC007 drug (which neutralises some of these autoantibodies) is in phase 2 trials.

If you have new joint pain, persistent fatigue with positive ANA / RF, new thyroid abnormalities, or other autoimmune features after COVID, a rheumatology workup is worth pursuing.

Other overlaps worth screening for

• hEDS (hypermobile Ehlers-Danlos Syndrome). Often uncovered rather than caused by COVID; the joint hypermobility and connective tissue features predate but become more apparent during dysautonomia. Worth screening (Beighton score) in Long COVID patients with POTS.
• Small fibre neuropathy. Reduced small nerve fibre density on skin biopsy in a subset, particularly with neuropathic pain or autonomic neuropathic features.
• Fibromyalgia. Widespread nociplastic pain after COVID is common; the overlap with Long COVID-PEM is substantial.
• Sleep apnea. The most-missed treatable mimic of post-viral fatigue.
• Iron deficiency. Functional deficiency (ferritin under 75) is routine.
• Thyroid disease. Post-COVID thyroiditis is documented.
• New-onset gastroparesis and IBS. The COVID GI footprint is real.
• Endometriosis. Patients report cycle changes and worsening pelvic pain after COVID.
• Depression and anxiety. Largely consequences of the illness and its dismissal; treatment is worthwhile (choose medications carefully, SNRIs and LDA often better-tolerated than SSRIs in Long COVID).

The current scientific picture

The biology of Long COVID is plural and converging. Major mechanistic strands with real evidence behind them:

• Persistent viral antigen. SARS-CoV-2 spike protein and viral RNA in tissue (gut, brain, lymph nodes) months after acute infection. Whether actively replicating or just reservoir is debated.
• Endothelial dysfunction and microclots. Persistent fibrinoloid microclots blocking small vessels (Pretorius, Kell). Endothelial damage on biopsy.
• Autoantibodies. Antibodies against adrenergic and muscarinic receptors, ACE2, and other targets. Drives the BC007 trial.
• Mitochondrial impairment. Reduced ATP production, abnormal aerobic recovery on Workwell 2-day CPET (the same protocol used for ME/CFS).
• Reactivated herpesviruses. EBV, HHV-6 commonly reactivated; sometimes treatable.
• Neuroinflammation. Iwasaki and colleagues: reduced regulatory T cells, pro-inflammatory microglia, persistent NF-kB activation in cognitive symptoms.
• Cerebral hypoperfusion. Large drops in cerebral blood flow on standing even when standard HR/BP look near-normal.
• Microbiome disruption. Distinct post-COVID gut-microbiome signatures persist.
• Mast cell activation. Newly-onset MCAS pattern in many patients.

None of these mechanisms is universal across all Long COVID patients; phenotype matters. Patients with prominent PEM look biologically more like ME/CFS; patients with prominent dyspnea look more like the cardiopulmonary phenotype; patients with prominent flushing and food reactions look more like MCAS.

Historical timeline

Active research directions

• BC007. Autoantibody-neutralising drug. Phase 2 trials in Long COVID. Possibly the most-watched single drug candidate.
• Triple anticoagulation. Heparin + clopidogrel + apixaban for the microclot subset. Controlled trials needed; private-clinic use ahead of evidence.
• Anti-IL-6 (tocilizumab) and immunomodulators. For autoimmune-pattern Long COVID.
• GLP-1 agonists (tirzepatide, semaglutide). Anecdotal reports of significant improvement; mechanism unclear.
• Paxlovid for established Long COVID. Stanford PaxLC trial showed limited benefit; persistent-virus hypothesis keeps research interest alive.
• HBOT (hyperbaric oxygen therapy). Israeli RCTs showed cognitive benefit; replication and access limited.
• Stellate ganglion block. Calms sympathetic outflow; explored for hyperadrenergic / dysautonomic subset.
• Microbiome interventions. FMT and defined microbial consortia in trials.
• Iwasaki's continued immune-signature work at Yale.
• NIH RECOVER trials phase. Finally launched in 2023-2024 after years of criticism; results coming.

Key sources worth knowing

• Patient-Led Research Collaborative. Patient researchers who have shaped the agenda on PEM, dysautonomia, and Long COVID phenotyping. Their 2021 paper is one of the most-cited Long COVID publications.
• Akiko Iwasaki's lab at Yale. Leading immunology research on Long COVID; preprints often available on bioRxiv.
• Pretorius and Kell on microclots. The microvascular damage story, with controversy around clinical translation.
• Bateman Horne Center. Has expanded Long COVID into its ME/CFS clinical framework; useful clinician resources.
• Open Medicine Foundation. Crosses Long COVID and ME/CFS; runs the You + ME Registry.
• RECOVER (NIH). The largest US research initiative; observational data useful, trials coming.
• Health Rising (Cort Johnson). The community's translator-in-chief for Long COVID and ME/CFS research.
• MEAction. ME/CFS patient advocacy that has expanded Long COVID resources.

Content creators worth following

These are the names that come up again and again in r/covidlonghaulers, r/cfs, and the wider Long COVID community, sorted by what the community actually shares. The Reddit citation under each card is the thread the recommendation traces back to, so you can see why they're trusted (or contested).

Patient-led research and journalism

Research labs and clinical centres

Podcasts and lived-experience media

Tools and trackers

The contested zone, brain-retraining and recovery-story creators

The brain-retraining and "you can cure yourself" industry that grew around ME/CFS expanded heavily into Long COVID. The community is genuinely split. Some patients credit them with real improvement; others have been actively harmed by stopping pacing to try a cure. Here are the most-shared, with the controversy made explicit.

Resources and community

• r/covidlonghaulers and r/cfs on Reddit. Well-moderated chronic-illness communities; the practical knowledge is real.
• Body Politic. Legacy community organising hub.
• Patient-Led Research Collaborative. Research-engaged community.
• MEAction local chapters. Country and state-level patient advocacy that has expanded Long COVID resources.
• Long COVID Alliance and Long COVID Action Project. Policy and advocacy.
• Long COVID Physio. International network of physiotherapists working on Long COVID with pacing-aware practice.
• You + ME Registry (OMF). Patient-contributed data registry; participating both helps research and connects you to studies.

Where to start if you've just been diagnosed

1. Screen for PEM. If positive, pace. Refuse GET.
2. Get a stand test (NASA Lean or tilt-table). Treat POTS if present.
3. Workup for treatable mimics: sleep apnea, iron deficiency, thyroid, B12, vitamin D, reactivated EBV / HHV-6.
4. Screen for MCAS pattern; trial H1/H2 antihistamines if suggestive.
5. Start disability paperwork early; documentation is easier in the worst months.
6. Find one Long-COVID-literate clinician (Bateman Horne, OMF, MEAction can help).
7. Educate one person who will be your advocate when you can't speak for yourself.
8. Try one off-label medication at a time, starting with LDN. Allow 6-8 weeks per trial.
9. Protect against reinfection where possible.
10. Be skeptical of cure narratives.

About this reference

This is a living document. It will be updated as new research emerges, as community-sourced Reddit research is woven in, and as patients tell us what is missing. The medical claims here are drawn from the listed organisations, peer-reviewed Long COVID literature, and ME/CFS clinical experience that translates directly. None of this is personal medical advice. For your situation specifically, talk with a clinician familiar with post-viral illness, preferably one who reads post-2022 dysautonomia and ME/CFS literature.